Meaningful change in oncology quality-of-life instruments: a systematic literature review

References

• Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual. Life Res. 11(3), 207–221 (2002).
   PubMed Web of Science ®Google Scholar
• Osoba D. A taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results. Med. Care 40, III31–III38 (2002).
   PubMedGoogle Scholar
• Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T; Clinical Significance Consensus Meeting Group. Estimating clinically significant differences in quality of life outcomes. Qual. Life Res. 14(2), 285–295 (2005).
   PubMed Web of Science ®Google Scholar
• Lydick E, Epstein RS. Interpretation of quality of life changes. Qual. Life Res. 2(3), 221–226 (1993).
   PubMed Web of Science ®Google Scholar
• Marquis P, Chassany O, Abetz L. A comprehensive strategy for the interpretation of quality-of-life data based on existing methods. Value Health 7(1), 93–104 (2004).
   PubMed Web of Science ®Google Scholar
• Eton DT, Cella D, Yost KJ et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J. Clin. Epidemiol. 57(9), 898–910 (2004).
   PubMed Web of Science ®Google Scholar
• Maringwa JT, Quinten C, King M et al.; EORTC PROBE Project and the Lung Cancer Group. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support. Care Cancer 19(11), 1753–1760 (2011).
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR; Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin. Proc. 77(4), 371–383 (2002).
   PubMed Web of Science ®Google Scholar
• Cella D, Eton DT, Fairclough DL et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J. Clin. Epidemiol. 55(3), 285–295 (2002).
   PubMed Web of Science ®Google Scholar
• Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy – Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 12(1), 124–129 (2009).
   PubMed Web of Science ®Google Scholar
• Askew RL, Xing Y, Palmer JL, Cella D, Moye LA, Cormier JN. Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire. Value Health 12(8), 1144–1150 (2009).
   PubMed Web of Science ®Google Scholar
• Eton DT, Cella D, Bacik J, Motzer RJ. A brief symptom index for advanced renal cell carcinoma. Health Qual. Life Outcomes 4, 68 (2006).
   PubMedGoogle Scholar
• Colwell HH, Mathias SD, Turner MP et al. Psychometric evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness. Oncologist 15(3), 308–316 (2010).
   PubMed Web of Science ®Google Scholar
• Eton DT, Cella D, Yount SE, Davis KM. Validation of the Functional Assessment of Cancer Therapy – Lung symptom index-12 (FLSI-12). Lung Cancer 57(3), 339–347 (2007).
   PubMed Web of Science ®Google Scholar
• Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual. Life Outcomes 5, 70 (2007).
   PubMed Web of Science ®Google Scholar
• Maringwa J, Quinten C, King M et al.; EORTC PROBE Project and Brain Cancer Group. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann. Oncol. 22(9), 2107–2112 (2011).
   PubMed Web of Science ®Google Scholar
• Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur. J. Haematol. 87(4), 330–337 (2011).
   PubMed Web of Science ®Google Scholar
• Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy – Biologic Response Modifiers (FACT-BRM) instrument. Value Health 8(2), 117–127 (2005).
   PubMed Web of Science ®Google Scholar
• Ringash J, Bezjak A, O’Sullivan B, Redelmeier DA. Interpreting differences in quality of life: the FACT-H&N in laryngeal cancer patients. Qual. Life Res. 13(4), 725–733 (2004).
   PubMed Web of Science ®Google Scholar
• Ringash J, O’Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer 110(1), 196–202 (2007).
   PubMed Web of Science ®Google Scholar
• Steel JL, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann. Oncol. 17(2), 304–312 (2006).
   PubMed Web of Science ®Google Scholar
• Cella D, Yount S, Du H et al. Development and validation of the Functional Assessment of Cancer Therapy – Kidney Symptom Index (FKSI). J. Support. Oncol. 4(4), 191–199 (2006).
   PubMedGoogle Scholar
• No authors listed. Cancer pain relief and palliative care. Report of a WHO expert committee. World Health Organ. Tech. Rep. Ser. 804, 1–75 (1990).
   PubMedGoogle Scholar
• Funk GF, Karnell LH, Smith RB, Christensen AJ. Clinical significance of health status assessment measures in head and neck cancer: what do quality-of-life scores mean? Arch. Otolaryngol. Head Neck Surg. 130(7), 825–829 (2004).
   PubMedGoogle Scholar
• Lemieux J, Beaton DE, Hogg-Johnson S, Bordeleau LJ, Goodwin PJ. Three methods for minimally important difference: no relationship was found with the net proportion of patients improving. J. Clin. Epidemiol. 60(5), 448–455 (2007).
   PubMed Web of Science ®Google Scholar
• Kvam AK, Fayers P, Wisloff F. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur. J. Haematol. 84(4), 345–353 (2010).
   PubMed Web of Science ®Google Scholar
• Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J. Clin. Oncol. 19(5), 1266–1274 (2001).
   PubMed Web of Science ®Google Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med. Care 41, 582–592 (2003).
   PubMed Web of Science ®Google Scholar
• Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA; Clinical Significance Consensus Meeting Group. Assessing meaningful change in quality of life over time: a users’ guide for clinicians. Mayo Clin. Proc. 77(6), 561–571 (2002).
   PubMed Web of Science ®Google Scholar